PharmaRadar360

PharmaRadar360

OncologyDrug intelligence

Keytruda

Pembrolizumab

PD-1 immune checkpoint inhibitor. Developed by Merck. Clinical, regulatory, and source evidence are connected below.

Company
Merck
Target / MOA
PD-1 路 PDCD1
Aliases
Keytruda 路 MK-3475
Signals
26
Clinical trials
20
Approvals
2
Evidence sources
26

Latest signals

What changed

The three most recent source-backed changes linked to this drug.

clinical trialClinicalTrials.gov

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Phase 1 路 ACTIVE_NOT_RECRUITING 路 Servier Bio-Innovation LLC

clinical trialClinicalTrials.gov

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Phase 3 路 RECRUITING 路 National Cancer Institute (NCI)

clinical trialClinicalTrials.gov

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 路 RECRUITING 路 National Cancer Institute (NCI)

Clinical trials

Key active studies

A focused view of recently updated studies 路 20 linked records.

Phase 1ACTIVE NOT RECRUITINGNCT06116136

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Servier Bio-Innovation LLC 路 Updated Apr 3, 2026

Phase 3RECRUITINGNCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 2RECRUITINGNCT04671667

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 2RECRUITINGNCT06770582

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 1ACTIVE NOT RECRUITINGNCT03030378

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 1RECRUITINGNCT06439836

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Source evidence

Where this profile comes from

Facts link back to original registries, regulators, labels, and publishers. Counts change as source records update.

ClinicalTrials.govofficial 路 Latest Apr 3, 202620FDAofficial 路 Latest Sep 19, 20252EMA Human Medicinesofficial 路 Latest Mar 18, 20261
Professional referenceThis profile summarizes linked public evidence. It is not medical, legal, regulatory, or investment advice. Verify decisions against original sources.